Shares of biotech firm Neurocrine Biosciences (NBIX) topped again today the list of biggest gainers among tickers on the Nasdaq and NYSE. Shares of NBIX rallied for the second straight day, up 24% at $4.22. Neurocrine shares surged on Tuesday after the company announced its drug to treat endometriosis had achieved its main and secondary goals in a study.
“The Daisy PETAL study was successful, all primary and secondary efficacy endpoints were met, and provided exactly the information we need to move this program forward,” Chris O’Brien, M.D., Chief Medical Officer at Neurocrine said in a statement.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!